Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pediatrix Medical Group, Inc.MD · Entity 4451 | EVP, GC & Corp Sec | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pediatrix Medical Group, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,036 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 20,036 · Balance 20,036 F1: Restricted shares granted pursuant to the Issuer's Second Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on June 1, 2027, twenty-five percent (25%) of the restricted shares will vest on June 1, 2028 and fifty percent (50%) of the restricted shares will vest on June 1, 2029, subject to the terms of the Plan. |
| Performance Share UnitSEC Table II · derivative / convertible security | Direct | 51,000 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 51,000 · Balance 51,000 F2: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs vest upon the satisfaction of both a service-based condition and a performance-based condition. The PSUs will vest, to the extent earned, on the three-year anniversary of the grant date, with the shares underlying the PSUs being earned in one-third installments based on the Issuer achieving stock price hurdles equal to 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days before the third anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares granted pursuant to the Issuer's Second Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on June 1, 2027, twenty-five percent (25%) of the restricted shares will vest on June 1, 2028 and fifty percent (50%) of the restricted shares will vest on June 1, 2029, subject to the terms of the Plan.
F2: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs vest upon the satisfaction of both a service-based condition and a performance-based condition. The PSUs will vest, to the extent earned, on the three-year anniversary of the grant date, with the shares underlying the PSUs being earned in one-third installments based on the Issuer achieving stock price hurdles equal to 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days before the third anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MAGELLAN HEALTH INC
Report date January 04, 2022 · Filed January 04, 2022
Section 16 reporting ended · disclosed 2022-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 1
1 source rowRow 1 · 2022-01-04 · Disposition to issuer · Disposed 2,961 · Balance 0 F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-04 · Disposition to issuer · Disposed 8,473 · Balance 0 F2: Not applicable. F3: These unvested restricted stock units previously granted by the Issuer on March 2, 2020 , which provided for vesting in equal increments on each of March 2, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-01-04 · Disposition to issuer · Disposed 11,309 · Balance 0 F2: Not applicable. F4: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-01-04 · Disposition to issuer · Disposed 10,605 · Balance 0 F2: Not applicable. F5: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration").
F2: Not applicable.
F3: These unvested restricted stock units previously granted by the Issuer on March 2, 2020 , which provided for vesting in equal increments on each of March 2, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
F4: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
F5: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 21:30 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantPerformance Share Unit · Derivative | 51,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-281304 · ownership.xml · derivative · entry 2 Haddock David · CIK 0001501357 · EVP, GC & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs vest upon the satisfaction of both a service-based condition and a performance-based condition. The PSUs will vest, to the extent earned, on the three-year anniversary of the grant date, with the shares underlying the PSUs being earned in one-third installments based on the Issuer achieving stock price hurdles equal to 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days before the third anniversary of the grant date. F2 · derivative.exercise_date: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs vest upon the satisfaction of both a service-based condition and a performance-based condition. The PSUs will vest, to the extent earned, on the three-year anniversary of the grant date, with the shares underlying the PSUs being earned in one-third installments based on the Issuer achieving stock price hurdles equal to 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days before the third anniversary of the grant date. F2 · derivative.expiration_date: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs vest upon the satisfaction of both a service-based condition and a performance-based condition. The PSUs will vest, to the extent earned, on the three-year anniversary of the grant date, with the shares underlying the PSUs being earned in one-third installments based on the Issuer achieving stock price hurdles equal to 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days before the third anniversary of the grant date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:30 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 20,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-281304 · ownership.xml · nonDerivative · entry 1 Haddock David · CIK 0001501357 · EVP, GC & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,036 F1 · kind: Restricted shares granted pursuant to the Issuer's Second Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on June 1, 2027, twenty-five percent (25%) of the restricted shares will vest on June 1, 2028 and fifty percent (50%) of the restricted shares will vest on June 1, 2029, subject to the terms of the Plan. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:10 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerPerformance-Based Restricted Stock Units · Derivative | 10,605 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-000967 · doc4.xml · derivative · entry 4 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,605 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F5 · price: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F5 · derivative.exercise_date: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. F5 · derivative.underlying_shares: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:10 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerRestricted Stock Units · Derivative | 11,309 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-000967 · doc4.xml · derivative · entry 3 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,309 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F4 · price: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F4 · derivative.exercise_date: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. F4 · derivative.underlying_shares: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:10 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerRestricted Stock Units · Derivative | 8,473 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-000967 · doc4.xml · derivative · entry 2 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,473 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F3 · price: These unvested restricted stock units previously granted by the Issuer on March 2, 2020 , which provided for vesting in equal increments on each of March 2, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F3 · derivative.exercise_date: These unvested restricted stock units previously granted by the Issuer on March 2, 2020 , which provided for vesting in equal increments on each of March 2, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. F3 · derivative.underlying_shares: These unvested restricted stock units previously granted by the Issuer on March 2, 2020 , which provided for vesting in equal increments on each of March 2, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:10 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerOrdinary Common Stock, $0.01 par value | 2,961 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-000967 · doc4.xml · nonDerivative · entry 1 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). F1 · price: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 18:34 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantRestricted Stock Units · Derivative | 11,309 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017982 · doc4.xml · derivative · entry 4 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 Underlying: Common Stock · 11,309 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F2 · price: Not applicable. F6 · derivative.exercise_date: Restricted Stock Units shall vest in one third increments on each of March 3 of 2022, 2023 and 2024. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 18:34 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Exercise / conversionRestricted Stock Units · Derivative | 4,237 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017982 · doc4.xml · derivative · entry 3 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,473 Underlying: Common Stock · 4,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not applicable. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on March 2, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. F5 · derivative.exercise_date: The remainder of 8,473 Restricted Stock Units shall vest in equal increments on March 2, 2022 and 2023. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 18:34 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Tax withholdingOrdinary Common Stock, $0.01 par value | 1,276 | $93.00 | $118,668.00 |
DisclosureSEC source: 0001209191-21-017982 · doc4.xml · nonDerivative · entry 2 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,961 F3 · kind: Represents the portion of shares withheld by the Company in order to pay taxes. F4 · price: Closing price on NASDAQ on March 2, 2021. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 18:34 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Exercise / conversionOrdinary Common Stock, $0.01 par value | 4,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017982 · doc4.xml · nonDerivative · entry 1 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on March 2, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 13:55 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantRestricted Stock Units · Derivative | 12,710 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015943 · doc4.xml · derivative · entry 2 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,710 Underlying: Common Stock · 12,710 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F4 · derivative.exercise_date: Restricted Stock Units vest in one third increments on March 2nd of each of 2021, 2022 and 2023. F1 · derivative.expiration_date: Not applicable. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 13:55 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantPerformance-Based Restricted Stock Units · Derivative | 10,605 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015943 · doc4.xml · derivative · entry 1 Haddock David · CIK 0001501357 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,605 Underlying: Common Stock · 10,605 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F2 · derivative.expiration_date: On the third anniversary of the grant date, Performance-Based Restricted Stock Units ("PSUs") vest based on achievement of total shareholder return ("TSR") performance relative to the S&P Health Services Industry Index over a three-year period beginning in 2020 and ending in 2022. Payout for vested PSUs ranges from 0% to 200% of the indicated number of shares, based on the Company's TSR percentile ranking compared to the TSR of the companies included in the selected market index. TSR is measured generally as the increase or decrease in the market value of the Company common stock with a deemed reinvestment of any dividends. If a participant terminates employment prior to the third anniversary of the grant date, the PSUs generally will be forfeited. PSUs have no voting rights and are generally non-transferable. The indicated number of PSUs assumes 100% vesting, and the actual number of shares issued in settlement of the PSUs may be greater or less than the indicated number. F3 · derivative.expiration_date: (Continuation of Footnote 3) - Since the payout for PSUs can range from 0% to 200%, the maximum number of shares that could vest and be issued could be double the indicated number. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.